Value Based Pricing Who Guideline On Country Pharmaceutical Pricing Policies A Plain Language Summary
Download Value Based Pricing Who Guideline On Country Pharmaceutical Pricing Policies A Plain Language Summary full books in PDF, epub, and Kindle. Read online free Value Based Pricing Who Guideline On Country Pharmaceutical Pricing Policies A Plain Language Summary ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
Author | : |
Publisher | : World Health Organization |
Total Pages | : 70 |
Release | : 2020-09-29 |
Genre | : Business & Economics |
ISBN | : 9240011870 |
In recent years, high prices of pharmaceutical products have posed challenges in high- and low-income countries alike. In many instances, high prices of pharmaceutical products have led to significant financial hardship for individuals and negatively impacted on healthcare systems' ability to provide population-wide access to essential medicines. Pharmaceutical pricing policies need to be carefully planned, carried out, and regularly checked and revised according to changing conditions. Strong, well-thought-out policies can guide well-informed and balanced decisions to achieve affordable access to essential health products. This guideline replaces the 2015 WHO guideline on country pharmaceutical pricing policies, revised to reflect the growing body of literature since the last evidence review in 2010. This update also recognizes country experiences in managing the prices of pharmaceutical products.
Author | : |
Publisher | : World Health Organization |
Total Pages | : 2 |
Release | : 2021-06-21 |
Genre | : Business & Economics |
ISBN | : 924002459X |
Author | : Ramesh Bhardwaj |
Publisher | : Taylor & Francis |
Total Pages | : 251 |
Release | : 2024-08-01 |
Genre | : Business & Economics |
ISBN | : 1040106536 |
This book provides a comprehensive examination of the pharmaceutical and medical device industry, including analysis of its current trade and innovation strategies. Opening with a survey of the global pharmaceutical and medical device industry, Bhardwaj outlines the growing trade and trade interdependence among countries in the global supply chain. He adopts a trade competitiveness approach to analyze patterns of product specialization and examines the drug discovery process and its challenges in translating bioscientific knowledge into lifesaving products. Bhardwaj argues that further economic integration, collaborative R&D, and digital technologies may help accelerate productivity and address global challenges of escalating drug costs, neglected tropical diseases (NTDs), and pandemic risks. The book also considers how the industry may further green its supply chain, and thus contribute to SDG Goals 3 (Good Health and Wellbeing) and 12 (Responsible Consumption and Production), before closing on a review of China and India, major players who have the potential to become drivers of low-cost medical products and innovations. With its evidence-based analysis, this book will be of great interest to researchers in pharmaceutical studies, supply chain management, global health, and health economics, as well as policymakers and professionals interested in the global issues facing the industry.
Author | : National Academies of Sciences, Engineering, and Medicine |
Publisher | : National Academies Press |
Total Pages | : 235 |
Release | : 2018-03-01 |
Genre | : Medical |
ISBN | : 0309468086 |
Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.
Author | : |
Publisher | : World Health Organization |
Total Pages | : 2 |
Release | : 2021-06-21 |
Genre | : Business & Economics |
ISBN | : 9240024085 |
Author | : Peter J. Neumann |
Publisher | : Oxford University Press |
Total Pages | : 273 |
Release | : 2021 |
Genre | : Business & Economics |
ISBN | : 0197512887 |
The prescription drug market -- Proposed solutions for rising drug prices -- Measuring the value of prescription drugs -- Measuring drug value : whose job is it anyway? -- Institute for Clinical and Economic Review (ICER) -- Other US value assessment frameworks -- Do drugs for special populations warrant higher prices? -- Improving value measurement -- Aligning prices with value -- The path forward.
Author | : |
Publisher | : World Health Organization |
Total Pages | : 2 |
Release | : 2021-06-21 |
Genre | : Business & Economics |
ISBN | : 9240024654 |
Author | : National Academies of Sciences, Engineering, and Medicine |
Publisher | : National Academies Press |
Total Pages | : 103 |
Release | : 2020-01-27 |
Genre | : Medical |
ISBN | : 0309498511 |
To explore the role of the National Institutes of Health (NIH) in innovative drug development and its impact on patient access, the Board on Health Care Services and the Board on Health Sciences Policy of the National Academies jointly hosted a public workshop on July 24â€"25, 2019, in Washington, DC. Workshop speakers and participants discussed the ways in which federal investments in biomedical research are translated into innovative therapies and considered approaches to ensure that the public has affordable access to the resulting new drugs. This publication summarizes the presentations and discussions from the workshop.
Author | : Zaheer-Ud-Din Babar |
Publisher | : Springer |
Total Pages | : 410 |
Release | : 2014-12-05 |
Genre | : Business & Economics |
ISBN | : 3319121693 |
This book provides an overview of the global pharmaceutical pricing policies. Medicines use is increasing globally with the increase in resistant microbes, emergence of new treatments, and because of awareness among consumers. This has resulted in increased drug expenditures globally. As the pharmaceutical market is expanding, a variety of pharmaceutical pricing strategies and policies have been employed by drug companies, state organizations and pharmaceutical pricing authorities.
Author | : National Academies of Sciences, Engineering, and Medicine |
Publisher | : National Academies Press |
Total Pages | : 483 |
Release | : 2017-09-28 |
Genre | : Medical |
ISBN | : 0309459575 |
Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.